Structure (82ddee01 7ba8 4657 Aaca Ef1335278215 01)
Ranolazine Tablet, Extended Release
Product Images NDC 70771-1499
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Ranolazine (NDC 70771-1499). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Container Label 500mg (82ddee01 7ba8 4657 Aaca Ef1335278215 02)
This is a description of a drug called "Ranolazine" which comes in the form of extended-release tablets of 500 mg. The tablets should be swallowed whole and not crushed, broken or chewed. The usual dosage is mentioned in the package insert. The drug should be stored at room temperature between 20-25°C and in a tight container. The drug is manufactured by Catila Healthcare Ltd in India.*
Container Label 1000mg (82ddee01 7ba8 4657 Aaca Ef1335278215 03)
This is a prescription medication with the NDC code 70771-1500-6, containing 1000 mg of Ranolazine in each film-coated extended-release tablet. It is important to swallow the tablets whole without crushing, breaking, or chewing. The package insert should be consulted for details on the usual dosage and prescribing information. The medication must be stored at a temperature between 20° to 25°C (68° o 77°F) and dispensed in a light container (USP). This drug is manufactured by Cadia Healicare Lid in India. Keep all drugs out of reach of children.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
